Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Continuous Glucose Monitoring for Women With Gestational Diabetes

NCT: NCT06310356 · RECRUITING

NCT IDNCT06310356
StatusRECRUITING
Start Date2024-11-18
Completion2027-08

Brief Summary

There are a few ongoing large randomized controlled trials (RCT's) on continuous glucose monitoring (CGM) in women with gestational diabetes (GDM) powered for pregnancy outcomes. However, none of these studies included women diagnosed with early GDM. The CORDELIA trial is a Belgian open-label multi-centric RCT with 14 centers in women with GDM (including both early and late GDM). Women will be randomized 1/1 to either treatment with CGM (intervention group, Freestyle Libre 3) or continue with self-monitoring of blood glucose (SMBG) with glucometer in line with normal routine (control arm). The study ends at the postpartum oral glucose tolerance test (OGTT 6-24 weeks postpartum) to screen for glucose intolerance.

Frequently Asked Questions

What is Continuous Glucose Monitoring for Women With Gestational Diabetes?

Continuous Glucose Monitoring for Women With Gestational Diabetes is a clinical trial registered under NCT06310356. Current status: RECRUITING.

What is the status of NCT06310356?

The current status of NCT06310356 (Continuous Glucose Monitoring for Women With Gestational Diabetes) is: RECRUITING.

When did Continuous Glucose Monitoring for Women With Gestational Diabetes start?

Continuous Glucose Monitoring for Women With Gestational Diabetes started on 2024-11-18.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.